AUSiMED Multiple Sclerosis Neurology 3-month Fellowship at the Hadassah-Hebrew University Medical Center, Jerusalem, Israel

The Australia Israel Medical Research’s (AUSiMED) Fellowships Program is a specific vehicle to deliver cross-country opportunities for Australian and Israel clinicians or scientists to acquire new skills and expertise. AUSiMED is offering a 3-month fellowship, for an Australian neurologist, in the world leading Center of Multiple Sclerosis and Unit of Neuro-immunology at Hadassah-Hebrew University Medical Center in Jerusalem, Israel under the supervision of Professor Dimitrios Karussis, starting in January 2019.

The Center for Multiple Sclerosis (MS) at Hadassah-Hebrew University Medical Center is a new multidisciplinary center that coordinates the treatment and follow-up of MS patients in the Jerusalem area and its surroundings, and is a reference center for patients all over the country and abroad. Patients are examined by doctors of the center (Prof. Karussis and Dr. Vaknin-Dembinsky) and by physicians from the Department of Neurology (Prof. Abramsky, Prof. Ben-Hur, and Dr. Houry). Patients can receive an evaluation of their situation from specialists in urology (urinary and sexual problems), rehabilitation (motor problems), and neuropthalmology (vision problems).

What distinguishes the center is the combination of excellent clinical care together with immunological research performed in the Neuroimmunological Laboratory and the Department of Neurology, which allow the development and direct implementation of innovative therapies for the disease.

Prof. Dimitrios Karussis is an expert in neuroimmunology and Director of the Center for MS. He has in recent years initiated various clinical studies with novel drugs such as Linomide, with T cell vaccination and with stem cell transplantation (given in the framework of clinical trials). This therapeutic project has recently received a boost through collaboration with other centers in the world.

The Fellowship

The selected fellow will receive training for 3 months in research and clinical skills related to Hadassah’s advanced technologies (and clinical trials) using autologous adult stem cells of the mesenchymal type in Multiple Sclerosis and ALS. The fellow will also have the opportunity to participate in specialty clinics that include the MS clinic (including the pain and spasticity clinic) and follow up of the patients who have received stem cell therapy.

Costs covered by the Fellowship: return airfare for one person (economy), 3 months accommodation in Jerusalem (studio or 1 bedroom apartment), monthly stipend for living expenses (approximately AUD 4,000 per month).

Applicants should:

  • be certified neurologists preferably with some experience in the field of multiple sclerosis (not absolutely necessary); and
  • provide a letter of support from their home institution indicating a commitment to a position that will enable the knowledge and skills acquired in the Fellowship to be practiced and shared.

For further information please email Dr Karen Teshuva, AUSiMED Program Manager:

Applications should be emailed by 12 September 2018 to:

Please include: a cover letter, your curriculum vitae, and a letter of support from the home institution certifying that a position will be available on your return.

Additional information about the training:

The fellow will receive training in:

  • the basic techniques of stem cell preparation and culture;
  • the techniques for injection of the cells to patients;
  • the laboratory immunological tests used for the diagnosis and follow up of patients with neuroimmunological diseases;
  • Clinical trainingin the following areas:
    • Differential diagnosis of multiple sclerosis (MS) and related disorders (ADEM, NMO-spectrum etc).
    • Neurological presentations and management of systemic autoimmune, connective tissue diseases and CNS and PNS vasculitis.
    • Use of immunotherapies for relapsing-remitting MS
    • Treatment of progressive or aggressive MS and demyelinating diseases, including the use of chemotherapeutic agents, various monoclonal antibodies and stem cells
    • Interpretation of MRI and other advanced imaging techniques of relevance to MS and other similar diseases affecting the CNS (including functional MRI, OCT and novel tests for evaluation of the cognitive/neuropshychological and visual functions)
    • Use of symptomatic treatments for management of pain, spasticity, fatigue, bowel- or bladder-dysfunction; and
    • Rehabilitation of MS and chronic neuroloimmunological diseases